Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in Relapsed or Refractory CLL/SLL
NCT02966756Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2017
- Primary completion
- Dec 2030
- Countries
- 4
01
Overview
Phase 2, open-label trial of venetoclax in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 cohorts), sponsored by AbbVie Inc. Primary endpoint: Overall Response Rate up to 2 years. Started Oct 2017; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02966756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966756.